ConductScience.org, home

Paper20573153

Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches.

Coppola A and 2 others. Br J Haematol, 2010. Cited by 72 papers, by iCite.

Cite this record

ConductScience Library. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Papers, record 20573153. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20573153

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches.
PubMed
Journal
Br J Haematol
PubMed
Year
2010
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
72
iCite
Relative citation ratio, by iCite
2.44
iCite
Revised in PubMed
2010-08-19
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Coppola AAntonio
2Di Minno MNMatteo N D
3Santagostino EElena

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Factor VIIIMajor topic
Hemophilia AMajor topic
Immune ToleranceMajor topic
IsoantibodiesMajor topic
Evidence-Based Medicine
Humans
Male
Patient Selection
Prognosis

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02479087Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A PatientsBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.

PMIDTitleJournalYearIn PapersSource
41890554Treatment outcomes, safety, and characteristics of immune tolerance induction in patients with hemophilia B and inhibitors: a systematic review.Res Pract Thromb Haemost2026https://conductscience.org/library/papers/41890554PubMed
39583653Rescue immune tolerance induction with a recombinant factor Fc-fused VIII: prospective ReITIrate study of clinical, humoral and cellular immune responses.Ther Adv Hematol2024https://conductscience.org/library/papers/39583653PubMed
39558913Prediction of the chance of successful immune tolerance induction in persons with severe hemophilia A and inhibitors: a clinical prediction model.Res Pract Thromb Haemost2024https://conductscience.org/library/papers/39558913PubMed
38565097Consensus-Based Expert Recommendations on the Management of Hemophilia A in the Gulf Region.Acta Haematol2025https://conductscience.org/library/papers/38565097PubMed
38524060A Study of Clinical Profile and Treatment in Adult Hemophilia Patients with Special Reference to the Inhibitor Levels.Cureus2024https://conductscience.org/library/papers/38524060PubMed
37192286Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells.Blood2023https://conductscience.org/library/papers/37192286PubMed
35868021Management of haemophilia A with inhibitors: A regional cross-talk.Haemophilia2022https://conductscience.org/library/papers/35868021PubMed
34278191Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.Res Pract Thromb Haemost2021https://conductscience.org/library/papers/34278191PubMed
34262568Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16.Front Immunol2021https://conductscience.org/library/papers/34262568PubMed
32832483Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients.Int J Mol Cell Med2020https://conductscience.org/library/papers/32832483PubMed
32598171Clinical Care of Bone Health in Patients on the Immune Tolerance Induction's Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia.Clin Appl Thromb Hemost2020https://conductscience.org/library/papers/32598171PubMed
30865582New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey.Blood Transfus2020https://conductscience.org/library/papers/30865582PubMed
30545924Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A.Haematologica2019https://conductscience.org/library/papers/30545924PubMed
30411401Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.Eur J Haematol2019https://conductscience.org/library/papers/30411401PubMed
28920105The impact of von Willebrand factor on factor VIII memory immune responses.Blood Adv2017https://conductscience.org/library/papers/28920105PubMed
26830966Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.Int J Hematol2016https://conductscience.org/library/papers/26830966PubMed
25548513A new recombinant factor VIII: from genetics to clinical use.Drug Des Devel Ther2014https://conductscience.org/library/papers/25548513PubMed
25350962Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.Blood Transfus2014https://conductscience.org/library/papers/25350962PubMed
24922295Current and evolving features in the clinical management of haemophilia.Blood Transfus2014https://conductscience.org/library/papers/24922295PubMed
24333314Clinical use of factor VIII and factor IX concentrates.Blood Transfus2013https://conductscience.org/library/papers/24333314PubMed

See all 25 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
F82157PubTator's text mininghttps://conductscience.org/library/genes/2157

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20573153

GET https://conductscience.org/api/papers/v1/20573153/cited_by?page=2